RIGL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Rigel Pharmaceuticals Inc (RIGL) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has demonstrated strong financial performance in the latest quarter, with significant revenue, net income, and EPS growth. Despite a lack of significant trading trends or recent news, the technical indicators suggest a neutral to slightly positive outlook, and options data indicates a bearish sentiment that may provide a favorable entry point. The absence of Intellectia Proprietary Trading Signals does not detract from the long-term potential of the stock.
The MACD histogram is positive and expanding, indicating bullish momentum. RSI is neutral at 38.038, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot point of 34.819, with support at 33.444 and resistance at 36.195. Overall, the technical indicators suggest a neutral to slightly positive outlook.
Strong financial performance in Q3 2025, with revenue up 25.59% YoY, net income up 124.62% YoY, and EPS up 108.57% YoY. Gross margin increased to 93.16%.
No recent news or significant trading trends. Stock trend analysis indicates a potential short-term decline (-0.81% in the next day, -4.17% in the next week).
In Q3 2025, Rigel Pharmaceuticals reported a revenue increase to $69.46M (+25.59% YoY), net income increase to $27.9M (+124.62% YoY), EPS increase to 1.46 (+108.57% YoY), and gross margin improvement to 93.16% (+8.97%).
No recent analyst rating or price target changes available.
